Karen Akinsanya - 17 Sep 2026 Form 4 Insider Report for Schrodinger, Inc. (SDGR)

Reporting relationship: President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships
Issuer ticker: SDGR
Reported as of: 17 Sep 2026
Net transaction value: -$927,970
SEC form: 4
Accepted by SEC: 21 Sep 2026, 17:15:16 UTC
Prior SEC filing: 22 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Donald Shum, as attorney-in-fact for Karen Akinsanya

Filing notes and source

Key filing fact

Karen Akinsanya filed Form 4 for Schrodinger, Inc. (SDGR) on 21 Sep 2026.

Key facts

This page summarizes Karen Akinsanya's Form 4 filing for Schrodinger, Inc. (SDGR).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 21 Sep 2026, 17:15.

Change

Previous filing in this sequence was filed on 22 Jun 2026.
Current net transaction value: -$927,970.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001797672 Primary reporting owner

Akinsanya Karen

Relationship: President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships
Address: C/O SCHRODINGER, INC.,, 1540 BROADWAY, 24TH FLOOR, NEW YORK
Signature: /s/ Donald Shum, as attorney-in-fact for Karen Akinsanya
Signature date: 21 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SDGR transaction

Common Stock

Options Exercise

Transaction value
Shares: +31,599
Change %: +45%
Price: $4.34^*
Shares after: 101,555
Date: 17 Sep 2026
Ownership: Direct
Footnotes: F1, F2

SDGR transaction

Common Stock

Sale

Transaction value: -$280,000
Shares: -10,000
Change %: -9.8%
Price: $28.00
Shares after: 91,555
Date: 17 Sep 2026
Ownership: Direct
Footnotes: F1, F2

SDGR transaction

Common Stock

Sale

Transaction value: -$647,970
Shares: -21,599
Change %: -24%
Price: $30.00
Shares after: 69,956
Date: 17 Sep 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SDGR transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -31,599
Change %: -73%
Price: $0.000000^*
Shares after: 11,599
Date: 17 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 31,599
Exercise price: $4.34
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2025.

Footnote F2

Includes 63,545 unvested RSUs.

Footnote F3

This option was granted on November 29, 2018 and is fully vested.

SEC remarks

President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships